Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives.

Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need.

Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Biotechnology

Education

Walden Biosciences

Blaine Mckee

Andres Rodriguez-Roman

Thomas Miller

Sanja Sever

Ming Proschitsky

Joshua Lapin

Curt Dewan

Alex Duncan

The Scientific Team at Walden Biosciences focuses on pioneering the development of first-in-class, highly-targeted therapies for kidney disease. This team leverages deep expertise in kidney-specific biological pathways to drive drug discovery and development. Through collaboration and innovative research, the team aims to advance breakthrough medicines that can potentially reverse the progression of kidney disease, thereby transforming patient care.

Scientific Team

Leadership Team

Scientific Team

About

Team members

Other teams at Walden Biosciences

Leadership Team